http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Solidarity Community Federal Credit Union Selects Mahalo Banking to Upgrade Member Security, Elevate Digital Experience
-
Arrowhead Pharmaceuticals Inc. (ARWR) Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7
-
AgriFORCE Growing Systems Ltd (AGRI) Announces 1:100 Reverse Share Split
-
DeFi Technologies Provides Monthly Corporate Update: Subsidiary Valour Achieves Record C$1.3 Billion (US$922 Million) AUM, Reflecting a 57% Month-over-Month Increase and a 155% Rise Year-to-Date, and
-
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
-
AgriFORCE Announces Reverse Stock Split for Nasdaq Compliance
-
MemeWave 2025 - The First Online Conference Exploring the Future of Memecoins and Crypto Culture
-
Gilead Sciences (GILD) and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
-
Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now
-
Tantalus Systems Expands Its Board of Directors
-
New Deloitte Survey: Increasing Consumer Privacy and Security Concerns in the Generative AI Era
-
Purity, Potency of Pharmactive's Aged Black Garlic Affirmed by Analytical Fingerprints
-
CD&R Appoints Andy Callahan, Former CEO of Hostess Brands, as Operating Advisor
-
ABBYY Leads in QKS Group’s Intelligent Document Processing SPARK Matrix™ for Fourth Consecutive Year
-
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
-
Merck (MRK) Granted FDA Breakthrough Therapy Designation to Sacituzumab Tirumotecan
-
FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Ca
-
Dow (DOW) Appoints Karen S. Carter as COO
-
The 20 MSP Bolsters Southeastern Footprint with 37th Acquisition
-
Maze Therapeutics Announces Oversubscribed $115 Million Financing to Support Advancement of Clinical-Stage Programs and Future Pipeline
-
Dow Announces Appointment of Karen S. Carter as Chief Operating Officer
-
Cartesian Therapeutics (RNAC) Reports Positive Updated Results from Phase 2b Trial of Descartes-08
-
Immunocore (IMCR) announces reimbursement agreement in England for KIMMTRAK for the treatment of HLA-A*02:01-positive adults
-
TCN's 2024 U.S. Consumer Survey Reveals Continued Shifts in Consumer Sentiments
-
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial
-
Mega Matrix Announced that the English Version of Teen Campus Romance drama "Not Really Siblings" Was Released on FlexTV on December 2
-
Cunard reports record-breaking bookings in 2024
-
Allot Announces its New Service Gateway Tera III for Top Tier Telecom Operators
-
Fraser Institute News Release: Hiring by the federal government in excess of population growth cost taxpayers $7.5 billion in 2022/23
-
Space Battery Technology Market Size Projected to Reach $6.56 Billion by 2032 Playing a Critical Role in Space Exploration
-
RCI Banque discloses Capital Requirements following the 2024 SREP draft decision.
-
One Ambulance Can Save Lives: Okean Elzy and Open Eyes Aim to Reach Goal of 30 Vehicles at London Concert
-
Cirql™ Launches Industrially Compostable, Biodegradable Material Innovation for Footwear Brands
-
IRIS Software Group Announces Intent to Acquire Dext Software Ltd.
-
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
-
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
-
Arctic Wolf Recognized on the 2024 Fortune Future 50 List for its Sustained and Continued Business Growth
-
Monster Energy's Mia Brookes Wins First World Cup Title and Makes History at the FIS Snowboard World Cup Big Air in Beijing
-
DeFi Technologies to be Featured on Stocktwits Daily Rip Live
-
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
-
Doge Jones Industrial Average (DJI) Listed On Moonshot as Mission To Flip Dow Ramps Up
-
Over 90% of Ryan White HIV Program Patients Reached Viral Suppression (AHF)
-
Bombardier Confirms Reaching Settlement in Legal Dispute with Honeywell
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Winter Wonderland in the Heart of NYC: The Empire State Building Celebrates the Holiday Season with Extravagant Holiday Décor, Festive Movie Screenings, Special Lightings, and More
-
Lumina Gold Announces US$6.0 Million Wheaton Precious Draw
-
Capricor Therapeutics to Present at Upcoming Investor Conferences
-
Albemarle Corporation to Participate in Virtual Fireside Chat at the Deutsche Bank 9th Annual Lithium & Battery Supply Chain Conference
-
Inari Medical (NARI) Announces Reimbursement Approval for ClotTriever® Thrombectomy System in Japan and New Distribution Partnership with Medikit Co., Ltd.
-
Inari Medical Announces Reimbursement Approval for ClotTriever® Thrombectomy System in Japan and New Distribution Partnership with Medikit Co., Ltd.
